Back to search results
NCT06461442

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatment
University of California, Davis
~73 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:Cryotherapy5Fluorouracil

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Partial clearance rate
Measured over 3 months and 12 months

Conditions

Actinic Keratoses

Explore related trials

Actinic Keratosis

NCT06461442

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, Davis - Dermatology Department

    Sacramento, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Daniel Eisen, MD · PRINCIPAL_INVESTIGATOR · UC Davis Department of Dermatology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Has a clinical diagnosis of 10 or more AKs in the head, neck, or extremities areas
Able to give informed consent themselves
Willing to return for follow up visits

Exclusion

Cognitively Impaired
Incarcerated
Non-English speakers
Immuno-comprised status
Received any kind of treatment for AK within the past 2 months
Use of systemic retinoids within the past 3 months
Suspicion of cancer in the target area
Porphyria
Genetic skin cancer disorders
Allergy to trial drugs or peanut/soy products
Pregnancy or breast-feeding

What this trial measures

  • Partial clearance rate3 months and 12 months

    Proportion of patients with at least a 75% reduction in the number of baseline AK lesions within the selected treatment area